# A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

> **NCT00600119** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 207 (actual)

## Conditions studied

- Opioid Induced Constipation (OIC)

## Interventions

- **DRUG:** placebo
- **DRUG:** NKTR-118

## Key facts

- **NCT ID:** NCT00600119
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-03
- **Final completion:** 2009-04
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2015-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600119, "A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00600119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*